This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
The Strong Activation of p53 Tumor Suppressor Drives the Synthesis of the Enigmatic Isoform of DUSP13 Protein
by
Małgorzata Krześniak
Małgorzata Krześniak ,
Barbara Łasut-Szyszka
Barbara Łasut-Szyszka
,
Agnieszka Będzińska
Agnieszka Będzińska ,
Agnieszka Gdowicz-Kłosok
Agnieszka Gdowicz-Kłosok
and
Marek Rusin
Marek Rusin *
Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-101 Gliwice, Poland
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(7), 1449; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines12071449 (registering DOI)
Submission received: 23 May 2024
/
Revised: 21 June 2024
/
Accepted: 26 June 2024
/
Published: 28 June 2024
Abstract
The p53 tumor suppressor protein activates various sets of genes depending on its covalent modifications, which are controlled by the nature and intensity of cellular stress. We observed that actinomycin D and nutlin-3a (A + N) collaborate in inducing activating phosphorylation of p53. Our recent transcriptomic data demonstrated that these substances strongly synergize in the upregulation of DUSP13, a gene with an unusual pattern of expression, coding for obscure phosphatase having two isoforms, one expressed in the testes and the other in skeletal muscles. In cancer cells exposed to A + N, DUSP13 is expressed from an alternative promoter in the intron, resulting in the expression of an isoform named TMDP-L1. Luciferase reporter tests demonstrated that this promoter is activated by both endogenous and ectopically expressed p53. We demonstrated for the first time that mRNA expressed from this promoter actually produces the protein, which can be detected with Western blotting, in all examined cancer cell lines with wild-type p53 exposed to A + N. In some cell lines, it is also induced by clinically relevant camptothecin, by nutlin-3a acting alone, or by a combination of actinomycin D and other antagonists of p53-MDM2 interaction—idasanutlin or RG7112. This isoform, fused with green fluorescent protein, localizes in the perinuclear region of cells.
Share and Cite
MDPI and ACS Style
Krześniak, M.; Łasut-Szyszka, B.; Będzińska, A.; Gdowicz-Kłosok, A.; Rusin, M.
The Strong Activation of p53 Tumor Suppressor Drives the Synthesis of the Enigmatic Isoform of DUSP13 Protein. Biomedicines 2024, 12, 1449.
https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines12071449
AMA Style
Krześniak M, Łasut-Szyszka B, Będzińska A, Gdowicz-Kłosok A, Rusin M.
The Strong Activation of p53 Tumor Suppressor Drives the Synthesis of the Enigmatic Isoform of DUSP13 Protein. Biomedicines. 2024; 12(7):1449.
https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines12071449
Chicago/Turabian Style
Krześniak, Małgorzata, Barbara Łasut-Szyszka, Agnieszka Będzińska, Agnieszka Gdowicz-Kłosok, and Marek Rusin.
2024. "The Strong Activation of p53 Tumor Suppressor Drives the Synthesis of the Enigmatic Isoform of DUSP13 Protein" Biomedicines 12, no. 7: 1449.
https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines12071449
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.